CDKN3 is a member of the dual specificity protein phosphatase family that acts as a cyclin-dependent kinase inhibitor (1). CDKN3 has been shown to interact with and dephosphorylate specifically the CDK2 kinase thereby preventing it’s activation. CDKN3 has been reported to be deleted, mutated, or overexpressed in several kinds of cancers. Increased expression of CDKN3 leads to increased levels of kinase-associated phosphatase activity that inhibits the G(1)/S transition of the cell cycle by dephosphorylating the cyclin-dependent kinases (2).
CDI1, CIP2, FLJ25787, KAP, KAP1, MGC70625
1. Niculescu, M.D. et al : Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene. J Neurochem. 2004, 89(5):1252-9.
2. Yeh, C.T. et al: Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant. Biochem. Biophys. Res. Commun. 2003; 305(2):311-4
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Cancer, Cell Cycle, Ser/Thr Kinases